Zealand Pharma — Maj 2022

[exitnu]

“This transaction is an important step forward in executing on the strategic refocusing we outlined at the end of March, as we find partners for our commercial and late-stage assets and prioritize the research and development of innovative new peptide therapeutics,” said Adam Steensberg, MD, Chief Executive Officer of Zealand Pharma. “We believe MannKind is the right partner to fully leverage the value of V-Go and ensure its continued availability for the patients and prescribers who need it.”

[exitnu]

Stærk, og så er det kun en nyhed vedr. V-Go

[Svingtraderen]

13%!

[Svingtraderen]

ledelsen er så hurtige til at eksekvere på ny strategi - god timing med Q
&A

[ProinvestorNEWS]

Zealand Pharma sælger V-Go-insulinleveringsenhed for 10 mio. dollar https://www.proinvestor.com/investornyt/825478/zealand-pharma-saelger-v-go-insulinleveringsenhed-for-10-mio-dollar

[exitnu]

Biotek-boss efter frasalg: “I træsko­længder får vi formentlig det samme ind som vi har givet”

Salget af produktet V-Go for 10 mio. dollar up-front er nogenlunde samme pris, som selskabet betalte i 2020

https://borsen.dk/nyheder/virksomheder/zealand-pharma-foran-med-oprydningsplan-efter-salg

[exitnu]

Zealand Pharma banker op på børsen efter frasalg af insulinpumpe

Zealand Pharma henter lidt tilbage af det tabte på aktiemarkedet, efter selskabet har haft sucess med at sikre sig et frasalg af insulinpumpen V-Go.

https://medwatch.dk/Medicinal___Biotek/article14027335.ece

[Helge_LarsenPI-redaktør]

Flere spørgsmål til Q&A er meget velkommen.

[exitnu]

clinicaltrials.gov - May 18, 2022 Drug: Dasiglucagon Phase 3: "A Research Study to Investigate the Safety and Effect of Dasiglucagon as a Hypoglycemia Rescue Therapy and How it Works in the Body of Children Under 6 Years of Age With Type 1 Diabetes" (Not yet recruiting).

[Svingtraderen]

@exitnu - nogen fornemmelse hvorfor det fine momentum idag?

[Svingtraderen]

har set dit svar under bava, tak

[exitnu]

[Svingtraderen]

nu går den helt balalejka

[exitnu]

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)

[exitnu]

Sådan!

[Svingtraderen]

du er en stjerne tak

[exitnu]

"met the primary endpoint with statistical significance"

[exitnu]

https://www.globenewswire.com/news-release/2022/05/19/2446817/0/en/Zealand-Pharma-Announces-Positive-Results-from-Phase-3-Trial-of-Dasiglucagon-in-Pediatric-Patients-with-Congenital-Hyperinsulinism-CHI.html

[exitnu]

Dasiglucagon met the primary endpoint with statistical significance - reducing the requirement for intravenous glucose by 55% compared to placebo in this pediatric patient population (ages 7 days to 12 months) when compared to placebo.

[exitnu]

Dasiglucagon treatment was assessed as well-tolerated in this study and 11 out of 12 patients are continuing into the long-term safety extension study.
These data, together with data from a previously reported Phase 3 study in older children with CHI, are expected to form the basis of a new drug application (NDA) for dasiglucagon treatment in the management of CHI, with the U.S. Food and Drug Administration. Submission is anticipated by end of 2022.